Atrium Therapeutics Inc.
RNA | NASDAQ
$8.27
+$0.01 (+0.12%)
At close: Oct 30, 2026, 4:00 PM ET
$8.33
+$0.06 (+0.73%)
Pre-market:
Nov 2, 2026, 8:40 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
PE Ratio | -3.29 |
PEG Ratio | n/a |
PS Ratio | 13.56 |
PB Ratio | 1.22 |
P/FCF Ratio | -5.93 |
P/OCF Ratio | -6.14 |
OCF/S Ratio | -220.91 |
Debt / Equity Ratio | 0.02 |
Quick Ratio | 6.53 |
Current Ratio | 6.53 |
Asset Turnover | 0.07 |
Interest Coverage | n/a |
Return on Equity | -36.99% |
Return on Assets | -27.55% |
Return on Invested Capital | -31.92% |
Dividend Yield | n/a |
Payout Ratio | n/a |
FCF Payout Ratio | n/a |
Gross Profit Margin | 100% |
Net Profit Margin | -411.88% |
Pretax Profit Margin | -412.64% |
Operating Profit Margin | -412.58% |
FCF Margin | -228.67% |
EBITDA Margin | -410.91% |
Add to Watchlist
Select watchlists to add or remove RNA